REATA PHARMACEUTICALS INC-A (RETA) Fundamental Analysis & Valuation

NASDAQ:RETA • US75615P1030

Current stock price

172.36 USD
+0.04 (+0.02%)
At close:
172.4 USD
+0.04 (+0.02%)
After Hours:

This RETA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. RETA Profitability Analysis

1.1 Basic Checks

  • RETA had negative earnings in the past year.
  • RETA had a negative operating cash flow in the past year.
RETA Yearly Net Income VS EBIT VS OCF VS FCFRETA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 -100M -200M -300M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -17.43%, RETA is in the better half of the industry, outperforming 66.82% of the companies in the same industry.
  • With a Return On Equity value of -100.38%, RETA is not doing good in the industry: 62.56% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -17.43%
ROE -100.38%
ROIC N/A
ROA(3y)-43.32%
ROA(5y)-39.17%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RETA Yearly ROA, ROE, ROICRETA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 200 -200 400 -400

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for RETA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RETA Yearly Profit, Operating, Gross MarginsRETA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 -5K -10K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. RETA Health Analysis

2.1 Basic Checks

  • RETA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for RETA has been increased compared to 1 year ago.
  • There is no outstanding debt for RETA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
RETA Yearly Shares OutstandingRETA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M
RETA Yearly Total Debt VS Total AssetsRETA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 200M 400M 600M 800M

2.2 Solvency

  • An Altman-Z score of 2.68 indicates that RETA is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • RETA has a better Altman-Z score (2.68) than 73.46% of its industry peers.
  • RETA has a Debt/Equity ratio of 0.84. This is a neutral value indicating RETA is somewhat dependend on debt financing.
  • RETA has a Debt to Equity ratio of 0.84. This is in the lower half of the industry: RETA underperforms 69.19% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.84
Debt/FCF N/A
Altman-Z 2.68
ROIC/WACCN/A
WACC9.36%
RETA Yearly LT Debt VS Equity VS FCFRETA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 200M -200M 400M

2.3 Liquidity

  • A Current Ratio of 3.21 indicates that RETA has no problem at all paying its short term obligations.
  • With a Current ratio value of 3.21, RETA perfoms like the industry average, outperforming 46.45% of the companies in the same industry.
  • A Quick Ratio of 3.19 indicates that RETA has no problem at all paying its short term obligations.
  • RETA has a Quick ratio (3.19) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.21
Quick Ratio 3.19
RETA Yearly Current Assets VS Current LiabilitesRETA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. RETA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 64.40% over the past year.
  • RETA shows a strong growth in Revenue. In the last year, the Revenue has grown by 134.81%.
  • Measured over the past years, RETA shows a very negative growth in Revenue. The Revenue has been decreasing by -45.95% on average per year.
EPS 1Y (TTM)64.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%330.2%
Revenue 1Y (TTM)134.81%
Revenue growth 3Y-56.28%
Revenue growth 5Y-45.95%
Sales Q2Q%2885.04%

3.2 Future

  • Based on estimates for the next years, RETA will show a very strong growth in Earnings Per Share. The EPS will grow by 24.33% on average per year.
  • RETA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 250.01% yearly.
EPS Next Y20.24%
EPS Next 2Y21.45%
EPS Next 3Y33.26%
EPS Next 5Y24.33%
Revenue Next Year3350.89%
Revenue Next 2Y1128.24%
Revenue Next 3Y529.02%
Revenue Next 5Y250.01%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
RETA Yearly Revenue VS EstimatesRETA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B 1.5B 2B
RETA Yearly EPS VS EstimatesRETA Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 5 -5 10 15

More info and screens

Find the best growth stocksShow best growing peers

1

4. RETA Valuation Analysis

4.1 Price/Earnings Ratio

  • RETA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year RETA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RETA Price Earnings VS Forward Price EarningsRETA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RETA Per share dataRETA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4 -6

4.3 Compensation for Growth

  • A more expensive valuation may be justified as RETA's earnings are expected to grow with 33.26% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.45%
EPS Next 3Y33.26%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. RETA Dividend Analysis

5.1 Amount

  • RETA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

RETA Fundamentals: All Metrics, Ratios and Statistics

REATA PHARMACEUTICALS INC-A

NASDAQ:RETA (9/25/2023, 8:12:09 PM)

After market: 172.4 +0.04 (+0.02%)

172.36

+0.04 (+0.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-08
Earnings (Next)11-06
Inst Owners0.81%
Inst Owner Change0%
Ins Owners5.84%
Ins Owner Change0%
Market Cap5.79B
Revenue(TTM)23.48M
Net Income(TTM)-87.62M
Analysts53.33
Price Target175.9 (2.05%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)115.67%
Min EPS beat(2)-27.16%
Max EPS beat(2)258.5%
EPS beat(4)2
Avg EPS beat(4)57.72%
Min EPS beat(4)-27.16%
Max EPS beat(4)258.5%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)9369.69%
Min Revenue beat(2)20.81%
Max Revenue beat(2)18718.6%
Revenue beat(4)2
Avg Revenue beat(4)4655.35%
Min Revenue beat(4)-100%
Max Revenue beat(4)18718.6%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)53.21%
EPS NQ rev (1m)0%
EPS NQ rev (3m)13.57%
EPS NY rev (1m)35.98%
EPS NY rev (3m)25.36%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)51.67%
Revenue NY rev (1m)67.27%
Revenue NY rev (3m)122.64%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 246.55
P/FCF N/A
P/OCF N/A
P/B 66.32
P/tB 66.32
EV/EBITDA N/A
EPS(TTM)-2.98
EYN/A
EPS(NY)-4.48
Fwd EYN/A
FCF(TTM)-7.43
FCFYN/A
OCF(TTM)-7.39
OCFYN/A
SpS0.7
BVpS2.6
TBVpS2.6
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -17.43%
ROE -100.38%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-43.32%
ROA(5y)-39.17%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0.84
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 99.38%
Cap/Sales 4.78%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.21
Quick Ratio 3.19
Altman-Z 2.68
F-Score3
WACC9.36%
ROIC/WACCN/A
Cap/Depr(3y)160.48%
Cap/Depr(5y)185.33%
Cap/Sales(3y)56.48%
Cap/Sales(5y)36.16%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)64.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%330.2%
EPS Next Y20.24%
EPS Next 2Y21.45%
EPS Next 3Y33.26%
EPS Next 5Y24.33%
Revenue 1Y (TTM)134.81%
Revenue growth 3Y-56.28%
Revenue growth 5Y-45.95%
Sales Q2Q%2885.04%
Revenue Next Year3350.89%
Revenue Next 2Y1128.24%
Revenue Next 3Y529.02%
Revenue Next 5Y250.01%
EBIT growth 1Y-32.59%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-13.04%
EBIT Next 3Y33.8%
EBIT Next 5Y27.95%
FCF growth 1Y-59.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-59.35%
OCF growth 3YN/A
OCF growth 5YN/A

REATA PHARMACEUTICALS INC-A / RETA Fundamental Analysis FAQ

What is the fundamental rating for RETA stock?

ChartMill assigns a fundamental rating of 3 / 10 to RETA.


Can you provide the valuation status for REATA PHARMACEUTICALS INC-A?

ChartMill assigns a valuation rating of 1 / 10 to REATA PHARMACEUTICALS INC-A (RETA). This can be considered as Overvalued.


How profitable is REATA PHARMACEUTICALS INC-A (RETA) stock?

REATA PHARMACEUTICALS INC-A (RETA) has a profitability rating of 1 / 10.